Wilson's Disease with Depression: When Second-Line Antidepressants Have Not Achieved Symptom Relief

Depression can occur in Wilson's disease. When optimised second-line pharmacotherapy has not produced adequate improvement, a structured protocol defines the next clinical step.

Clinical Scenario

Patient with Wilson's disease presenting with depression, in whom second-line antidepressant pharmacotherapy has not produced improvement or resolution of depressive symptoms.

Previous Treatment — Goal Not Met

Second-line antidepressants — including TCAs, SNRIs, paroxetine, or mirtazapine — were trialled. The expected goal, improvement or resolution of depressive symptoms, was not achieved. This protocol addresses the next step after that failure.

Next Treatment Approach (Partial Overview)

The protocol identifies a procedure-based intervention indicated when depression in Wilson's disease has not responded to pharmacological treatment. The full clinical regimen and criteria are available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jhep.2024.11.007

The choice of SSRIs to treat depression in WD aligns with evidence of altered serotonergic neurotransmission in WD and SSRIs appear to be a reasonable choice as a first-line treatment.

ECT if resistance to pharmacological treatment

View source ↗